June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
FIRST-IN-MAN PANCREATIC ISLET TRANSPLANTATION IN THE ANTERIOR CHAMBER OF THE HUMAN EYE
Author Affiliations & Notes
  • Nadine Gerber-Hollbach
    Ophthalmology, University Hospital of Basel, Basel, Switzerland
  • Marc Donath
    Endocrinology, University Hospital of Basel, Basel, Switzerland
  • David Goldblum
    Ophthalmology, University Hospital of Basel, Basel, Switzerland
  • Pascal W. Hasler
    Ophthalmology, University Hospital of Basel, Basel, Switzerland
  • Beckey Trinh
    Endocrinology, University Hospital of Basel, Basel, Switzerland
  • Judith Siegenthaler
    Endocrinology, University Hospital of Basel, Basel, Switzerland
  • Matthias Hepprich
    Endocrinology, University Hospital of Basel, Basel, Switzerland
  • Thierry Berney
    Endocrinology, University Hospital of Geneva, Geneva, Switzerland
    Surgery, University Hospital of Geneva, Geneva, Switzerland
  • Domenico Bosco
    Endocrinology, University Hospital of Geneva, Geneva, Switzerland
  • Juerg Steiger
    Endocrinology, University Hospital of Basel, Basel, Switzerland
    Transplantation Immunology and Nephrology, University Hospital of Basel, Basel, Switzerland
  • Michael Dickenmann
    Transplantation Immunology and Nephrology, University Hospital of Basel, Basel, Switzerland
  • Christoph Henzen
    Medicine, Cantonal Hospital of Lucerne, Lucerne, Switzerland
  • Jeremy Meyer
    Surgery, University Hospital of Geneva, Geneva, Switzerland
  • Per-Olof Berggren
    Karolinska Institute, Stockholm, Sweden
  • Footnotes
    Commercial Relationships   Nadine Gerber-Hollbach, None; Marc Donath, None; David Goldblum, None; Pascal W. Hasler, None; Beckey Trinh, None; Judith Siegenthaler, None; Matthias Hepprich, None; Thierry Berney, None; Domenico Bosco, None; Juerg Steiger, None; Michael Dickenmann, None; Christoph Henzen, None; Jeremy Meyer, None; Per-Olof Berggren, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5592. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nadine Gerber-Hollbach, Marc Donath, David Goldblum, Pascal W. Hasler, Beckey Trinh, Judith Siegenthaler, Matthias Hepprich, Thierry Berney, Domenico Bosco, Juerg Steiger, Michael Dickenmann, Christoph Henzen, Jeremy Meyer, Per-Olof Berggren; FIRST-IN-MAN PANCREATIC ISLET TRANSPLANTATION IN THE ANTERIOR CHAMBER OF THE HUMAN EYE. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5592.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetes type I results from the destruction of pancreatic islets due to autoimmune attack against the insulin-producing beta cells in the endocrine pancreas. While ongoing clinical trials have focused on islet transplantation into the hepatic portal system with some success, the search for alternative islet transplantation sites remains important. One location of interest is the anterior chamber of the eye. We report the feasibility and proof of concept of transplantation of allogenic pancreatic human islets for the first time into the anterior chamber of a human eye.

Methods : About 40'000 freshly prepared and isolated allogenic human islets (95% purity in 200 microliter) were transplanted into the anterior chamber of a legally blind diabetic eye of a c-peptide negative diabetic patient. Follow up over 3 months regarding clinical examination of the eye as well as fasting blood serum c-peptide and blood sugar levels were regularly determined.

Results : IOP increased up to 50 mm Hg the first night, but normalized over the next weeks. No inflammation or other ophthalmic complications were found otherwise in the injected eye. After mixed meal tolerance test c-peptide levels were measurable in the peripheral blood.

Conclusions : Our results proof that allogenic human pancreatic islet transplantation can be performed without causing permanent damage to the eye and that transplanted islets will survive and be functional after 3 months.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×